These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32220885)

  • 41. PD-L1 expression and infiltration by CD4
    Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
    Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma.
    Yang M; Hlady RA; Zhou D; Ho TH; Robertson KD
    Cancer Med; 2019 Sep; 8(12):5760-5768. PubMed ID: 31361072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
    Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
    Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lactate dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma.
    Girgis H; Masui O; White NM; Scorilas A; Rotondo F; Seivwright A; Gabril M; Filter ER; Girgis AH; Bjarnason GA; Jewett MA; Evans A; Al-Haddad S; Siu KM; Yousef GM
    Mol Cancer; 2014 May; 13():101. PubMed ID: 24885701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PTEN Expression, Not Mutation Status in
    Voss MH; Chen D; Reising A; Marker M; Shi J; Xu J; Ostrovnaya I; Seshan VE; Redzematovic A; Chen YB; Patel P; Han X; Hsieh JJ; Hakimi AA; Motzer RJ
    Clin Cancer Res; 2019 Jan; 25(2):506-514. PubMed ID: 30327302
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MicroRNA expression profiles predict clinical phenotypes and prognosis in chromophobe renal cell carcinoma.
    Ge YZ; Xin H; Lu TZ; Xu Z; Yu P; Zhao YC; Li MH; Zhao Y; Zhong B; Xu X; Zhou LH; Wu R; Xu LW; Wu JP; Li WC; Zhu JG; Jia RP
    Sci Rep; 2015 May; 5():10328. PubMed ID: 25981392
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor signatures of PTHLH overexpression, high serum calcium, and poor prognosis were observed exclusively in clear cell but not non clear cell renal carcinomas.
    Yao M; Murakami T; Shioi K; Mizuno N; Ito H; Kondo K; Hasumi H; Sano F; Makiyama K; Nakaigawa N; Kishida T; Nagashima Y; Yamanaka S; Kubota Y
    Cancer Med; 2014 Aug; 3(4):845-54. PubMed ID: 24861371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential expression in clear cell renal cell carcinoma identified by gene expression profiling.
    Lane BR; Li J; Zhou M; Babineau D; Faber P; Novick AC; Williams BR
    J Urol; 2009 Feb; 181(2):849-60. PubMed ID: 19095258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
    Eichelberg C; Minner S; Isbarn H; Burandt E; Terracciano L; Moch H; Kell A; Heuer R; Chun FK; Sauter G; Fisch M; Tennstedt P
    World J Urol; 2013 Aug; 31(4):847-53. PubMed ID: 22009118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
    Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening.
    Han G; Zhao W; Song X; Kwok-Shing Ng P; Karam JA; Jonasch E; Mills GB; Zhao Z; Ding Z; Jia P
    BMC Genomics; 2017 Oct; 18(Suppl 6):678. PubMed ID: 28984208
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.
    Xiong Y; Liu L; Wang J; Xi W; Xia Y; Bai Q; Qu Y; Long Q; Xu J; Guo J
    Oncotarget; 2017 Apr; 8(15):25650-25659. PubMed ID: 27783999
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients.
    Fernandes FG; Silveira HCS; Júnior JNA; da Silveira RA; Zucca LE; Cárcano FM; Sanches AON; Neder L; Scapulatempo-Neto C; Serrano SV; Jonasch E; Reis RM; Evangelista AF
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668731
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
    Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
    Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
    Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.
    Shioi K; Komiya A; Hattori K; Huang Y; Sano F; Murakami T; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
    Clin Cancer Res; 2006 Dec; 12(24):7339-46. PubMed ID: 17189405
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
    Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
    Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes.
    Ged Y; Chen YB; Knezevic A; Donoghue MTA; Carlo MI; Lee CH; Feldman DR; Patil S; Hakimi AA; Russo P; Voss MH; Motzer RJ
    Clin Genitourin Cancer; 2019 Aug; 17(4):268-274.e1. PubMed ID: 31151928
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
    Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
    Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A cluster of metabolism-related genes predict prognosis and progression of clear cell renal cell carcinoma.
    Liu M; Pan Q; Xiao R; Yu Y; Lu W; Wang L
    Sci Rep; 2020 Jul; 10(1):12949. PubMed ID: 32737333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.